A nomogram using cytogenetics, TP53, and NPM1 mutational status can predict responses to induction chemotherapy in AML

Leuk Lymphoma. 2022 Dec;63(13):3257-3260. doi: 10.1080/10428194.2022.2118532. Epub 2022 Sep 8.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Cytogenetic Analysis
  • Cytogenetics
  • Humans
  • Induction Chemotherapy*
  • Leukemia, Myeloid, Acute* / diagnosis
  • Leukemia, Myeloid, Acute* / drug therapy
  • Leukemia, Myeloid, Acute* / genetics
  • Mutation
  • Nomograms
  • Nuclear Proteins / genetics
  • Prognosis
  • Tumor Suppressor Protein p53 / genetics
  • fms-Like Tyrosine Kinase 3

Substances

  • Nuclear Proteins
  • fms-Like Tyrosine Kinase 3
  • TP53 protein, human
  • Tumor Suppressor Protein p53